FARMINGDALE, N.Y.--(BUSINESS WIRE)--May 23, 2006--Enzo Biochem, Inc. (NYSE:ENZ - News): Enzo Biochem, Inc. (NYSE:ENZ - News) announced today that, as a result of a licensing agreement, it plans to enter into the cytogenetics market by producing newly patented single copy DNA probes that can identify the minutest strands of DNA, opening the door to more effective treatment of genetic diseases and some cancers. The Company plans to combine the probes with its proprietary signal amplification technologies, which will enhance their effectiveness by allowing visualization at levels not achievable by other methods.
